Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
about
Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Transcriptomic and metabolic responses of Staphylococcus aureus exposed to supra-physiological temperaturesIn vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleInvestigational treatments for postoperative surgical site infections.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureusCeftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.β-lactams against emerging 'superbugs': progress and pitfalls.Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Novel methicillin resistance gene mecD in clinical Macrococcus caseolyticus strains from bovine and canine sources.Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.
P2860
Q33239640-DCE08455-EAF6-4899-AF8E-CF366E9A2A06Q33433697-A5645DA5-D11A-48FD-B15E-D7EFF12CBC46Q33559139-0A0982D7-90CB-4F29-9E1B-4F2CA48CA562Q35026567-7E90146C-86E1-403A-A1CE-E21DF07FA9F4Q36715742-F966D46C-19EC-451F-B34E-5507A4B4D801Q36763997-88019E5C-32A8-4A47-9F47-2BC3F7DE294FQ37077629-6B4BE749-387F-4690-9809-F3AC46709022Q37247619-537CE364-2542-4C15-985A-22BC451F58BEQ37461413-D078C3B0-B11E-400B-A721-331C56C1B821Q37593094-FECE1488-75B0-487B-8827-63FB7A06EEB0Q38177344-F4407E6E-D397-4AD8-854D-681BB47FB2BEQ40600643-AD1EB2AB-FD39-4D8C-A6EF-63D212D4D131Q42133056-56DA15A3-71FA-4F60-8D2B-535C83BFE1DAQ43183402-22463CA7-95E7-42A3-BD35-48ADC01D7404Q43993247-DB7CE385-820C-4D9C-BE38-9CD5ED8716DF
P2860
Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@ast
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@en
type
label
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@ast
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@en
prefLabel
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@ast
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@en
P2093
P2860
P50
P1476
Intensive therapy with ceftobi ...... esistant Staphylococcus aureus
@en
P2093
Asllan Gjinovci
Daniel P Lew
Dongmei Li
P2860
P304
P356
10.1128/AAC.49.9.3789-3793.2005
P407
P577
2005-09-01T00:00:00Z